E-CADHERIN EXPRESSION IN PAPILLARY TRANSITIONAL-CELL CARCINOMA OF THE URINARY-BLADDER

被引:46
作者
ROSS, JS
DELROSARIO, AD
FIGGE, HL
SHEEHAN, C
FISHER, HAG
BUI, HX
机构
[1] ALBANY MED COLL,DEPT UROL SURG,ALBANY,NY 12208
[2] SAMUEL S STRATTON VET ADM MED CTR,DEPT PATHOL,ALBANY,NY
关键词
TRANSITIONAL CELL CARCINOMA; CELL ADHESION MOLECULE; E-CADHERIN;
D O I
10.1016/0046-8177(95)90081-0
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
E-cadherin (ECD), a cell adhesion molecule that plays a diverse role in cell-cell and cell-matrix interaction, has recently been associated with tumor invasion and metastasis. We evaluated the ECD expression in 55 cases of urinary bladder papillary transitional cell carcinoma using a double-linked immunoalkaline phosphatase procedure on formalin-fixed, paraffin-embedded specimens quantified as percentage positive staining area with the Roche RPW image analyzer (Roche Image Analysis Systems, Elon College, NC). The 10 grade I tumors stained intensely for ECD (66%) and showed enhanced staining compared with normal transitional epithelium. The 20 grade II lesions stained moderately at 45%, and the 25 grade III lesions showed weak expression of ECD with a 33% positive stain. This loss of expression for high-grade versus low-grade tumors was statistically significant (P<.02). There was a similar decrease in E-CD expression for high-stage versus low-stage specimens with 30 stage 0 and stage A cases having an average of 51% positive stain and 25 stage B, C, and D cases having an average stain of 33%. This difference was also statistically significant (P<.001). We conclude that loss of expression of ECD in high-grade, high-stage urinary bladder transitional cell carcinoma is associated with significant bladder wall invasion, indicates potential for metastasis, and may be of clinical value in the assessment of prognosis and planning of therapy for patients with bladder tumors. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:940 / 944
页数:5
相关论文
共 38 条
[1]  
ALBELDA SM, 1993, LAB INVEST, V68, P4
[2]  
BRINGUIER PP, 1993, CANCER RES, V53, P3241
[3]  
BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916
[4]  
COON JS, 1982, AM J CLIN PATHOL, V72, P692
[5]  
DALBAGNI G, 1993, DIAGN MOL PATHOL, V2, P41
[6]  
DORUDI S, 1993, AM J PATHOL, V142, P981
[7]  
ESRIG D, 1993, AM J PATHOL, V143, P1389
[8]   ACCUMULATION OF NUCLEAR P53 AND TUMOR PROGRESSION IN BLADDER-CANCER [J].
ESRIG, D ;
ELMAJIAN, D ;
GROSHEN, S ;
FREEMAN, JA ;
STEIN, JP ;
CHEN, SC ;
NICHOLS, PW ;
SKINNER, DG ;
JONES, PA ;
COTE, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (19) :1259-1264
[9]  
Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T
[10]  
GAMALLO C, 1993, AM J PATHOL, V142, P987